The safety of mesalamine in human pregnancy: A prospective controlled cohort study

被引:135
作者
Diav-Citrin, O
Park, YH
Veerasuntharam, G
Polachek, H
Bologa, M
Pastuszak, A
Koren, G
机构
[1] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Res Inst, Dept Pediat,Motherisk Program, Toronto, ON M5N 1X8, Canada
[2] Univ Toronto, Dept Pediat, Toronto, ON, Canada
[3] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[4] Univ Toronto, Dept Pharm & Med, Toronto, ON, Canada
关键词
D O I
10.1016/S0016-5085(98)70628-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Mesalamine is a first-line drug in the treatment of inflammatory bowel disease. Information regarding human pregnancy experience with mesalamine has been scarce and uncontrolled despite its frequent use in women of childbearing age. The aim of this study was to examine the fetal safety of mesalamine. Methods: The Motherisk Program prospectively enrolled and followed up 165 women exposed to mesalamine during pregnancy, 146 of whom had first trimester exposure. Pregnancy outcome was compared with that of a matched control group, who were counseled for nonteratogenic exposure. Results: There was no increase in major malformations (1 of 127 [0.8%] for mesalamine vs. 5 of 131 [3.8%] for nonteratogenic controls; P = 0.23). There was an increase in the rate of preterm deliveries (13.0% for mesalamine vs. 4.7% for nonteratogenic controls; P = 0.02), a decrease in the mean maternal weight gain during pregnancy (13.1 +/- 6.3 kg for mesalamine vs. 15.6 +/- 6.0 kg for nonteratogenic controls; P = 0.0002), and a decrease in the mean birth weight (3253 +/- 546 g for mesalamine vs. 3461 +/- 542 g for nonteratogenic controls; P = 0.0005). There were no significant differences in the maternal obstetric history, rates of live births, miscarriages, pregnancy terminations, ectopic pregnancies, delivery method, or fetal distress between the groups. Conclusions: This study suggests that mesalamine does not represent a major teratogenic risk in humans when used in the recommended doses.
引用
收藏
页码:23 / 28
页数:6
相关论文
共 33 条
[1]   A United States national reference for fetal growth [J].
Alexander, GR ;
Himes, JH ;
Kaufman, RB ;
Mor, J ;
Kogan, M .
OBSTETRICS AND GYNECOLOGY, 1996, 87 (02) :163-168
[2]  
ARBUCKLE L, 1995, DRUG INFORMATION COR
[3]  
*AXC PHARM, 1994, SAL PROD MON
[4]  
BAIOCCO PJ, 1984, J CLIN GASTROENTEROL, V6, P211
[5]   INCREASED RISK OF PRETERM BIRTH FOR WOMEN WITH INFLAMMATORY BOWEL-DISEASE [J].
BAIRD, DD ;
NARENDRANATHAN, M ;
SANDLER, RS .
GASTROENTEROLOGY, 1990, 99 (04) :987-994
[6]  
Behrman RE, 1992, NELSON TXB PEDIAT, V14th
[7]  
CAMPBELL L, 1995, M215B007 SMITHKL BEE
[8]   DISPOSITION OF 5-AMINOSALICYLIC ACID AND N-ACETYL-5-AMINOSALICYLIC ACID IN FETAL AND MATERNAL BODY-FLUIDS DURING TREATMENT WITH DIFFERENT 5-AMINOSALICYLIC ACID PREPARATIONS [J].
CHRISTENSEN, LA ;
RASMUSSEN, SN ;
HANSEN, SH .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1994, 73 (05) :399-402
[9]  
Cleandre D., 1993, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V22, P59
[10]   RENAL-INSUFFICIENCY IN INFANT - SIDE-EFFECT OF PRENATAL EXPOSURE TO MESALAZINE [J].
COLOMBEL, JF ;
BRABANT, G ;
GUBLER, MC ;
LOCQUET, A ;
COMES, MC ;
DEHENNAULT, M ;
DELCROIX, M .
LANCET, 1994, 344 (8922) :620-621